Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
[68Ga]Ga-NOTA-C2 (Peking Univ. Shenzhen Hospital): sourced facts only. name: "Two nanobodies, C2 and its albumin-binding derivative (ABDC2), specifically targeting CD47 were labeled with 68Ga." [PMID:40326602]; target: "Two nanobodies, C2 and its albumin-binding derivative (ABDC2), specifically targeting CD47 were labeled with 68Ga." [PMID:40326602]; developer: "Department of Nuclear Medicine, Peking University Shenzhen Hospital, Shenzhen 518036, Guangdong, China." [PMID:40326602]; modality: "Two nanobodies, C2 and its albumin-binding derivative (ABDC2), specifically targeting CD47 were labeled with 68Ga." [PMID:40326602]; stage: "Micro-PET imaging using [68Ga]Ga-NOTA-C2 and [68Ga]Ga-NOTA-ABDC2 demonstrated clear visualization of OCUT-2C tumors." [PMID:40326602]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on [68Ga]Ga-NOTA-C2 (Peking Univ. Shenzhen Hospital).